China’s Healthcare Sector Set for Foreign Investment Explosion
This article was originally published in PharmAsia News
Executive Summary
Foreign Direct Investment (FDI) into China's life sciences sector will increase by 177% to £128.2 billion by 2020, as the rapidly ageing population drives demand for healthcare services and the Chinese government makes efforts to relax controls. So says a new report from global law firm King & Wood Mallesons, Branching Out: Investment Opportunities in China in 2020.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.